Neurology & Neurotherapeutics - NE Outside Agreements

Research output

Research output per year 1984 2006 2007 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2023

• 278 Article
• 114 Review article
• 21 Editorial
• 19 Letter
• 31 More
  • 13 Comment/debate
  • 8 Conference contribution
  • 6 Short survey
  • 4 Chapter

Research output per year

Research output per year

Search results

• Review article

  A critical appraisal of treatment decisions in multiple sclerosisĝ€"old versus new

  Kieseier, B. C. & Stüve, O., May 2011, In: Nature Reviews Neurology. 7, 5, p. 255-262 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Glatiramer Acetate 41%
  • Neurologists 31%
  • Proxy 29%
  • Interferons 26%
  61 Scopus citations

• Acute disseminated encephalomyelitis: An update

  Menge, T., Hemmer, B., Nessler, S., Wiendl, H., Neuhaus, O., Hartung, H. P., Kieseier, B. C. & Stüve, O., Nov 2005, In: Archives of neurology. 62, 11, p. 1673-1680 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Acute Disseminated Encephalomyelitis 100%
  • Central Nervous System 52%
  • Vaccination 52%
  • Case Series 37%
  • Multiple Sclerosis 32%
  324 Scopus citations

• Acute disseminated encephalomyelitis: An acute hit against the brain

  Menge, T., Kieseier, B. C., Nessler, S., Hemmer, B., Hartung, H. P. & Stüve, O., Jun 2007, In: Current opinion in neurology. 20, 3, p. 247-254 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Acute Disseminated Encephalomyelitis 100%
  • Brain 33%
  • CNS Demyelinating Autoimmune Diseases 17%
  • Autoimmunity 9%
  • Multiple Sclerosis 8%
  136 Scopus citations

• Akute disseminierte enzephalomyelitis. Pathogenese, diagnose, behandlung und prognose

  Translated title of the contribution: Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosisStüve, O., Nessler, S., Hartung, H. P., Hemmer, B., Wiendl, H. & Kieseier, B. C., Jun 2005, In: Nervenarzt. 76, 6, p. 701-707 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Acute Disseminated Encephalomyelitis 100%
  • Demyelinating Diseases 28%
  • Vaccination 21%
  • Oligoclonal Bands 19%
  • Leukoencephalopathies 18%
  14 Scopus citations

• Alemtuzumab: The advantages and challenges of a novel therapy in MS

  Menge, T., Stüve, O., Kieseier, B. C. & Hartung, H. P., Jul 1 2014, In: Neurology. 83, 1, p. 87-97 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Alemtuzumab 100%
  • Antibodies, Monoclonal, Humanized 30%
  • Relapsing-Remitting Multiple Sclerosis 29%
  • Phase II Clinical Trials 29%
  • Phase III Clinical Trials 28%
  44 Scopus citations

• Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis

  Awad, A., Hemmer, B., Hartung, H. P., Kieseier, B., Bennett, J. L. & Stuve, O., Feb 2010, In: Journal of Neuroimmunology. 219, 1-2, p. 1-7 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Cerebrospinal Fluid 98%
  • Routine Diagnostic Tests 71%
  • Central Nervous System Diseases 41%
  • History 28%
  74 Scopus citations

• Approved and future pharmacotherapy for multiple sclerosis

  Stüve, O., Cree, B. C., Von Büdingen, H. C., Yousef, S., Bowen, J. D., Genain, C. P., Hauser, S. L., Steinman, L. & Zamvil, S. S., Sep 2002, In: Neurologist. 8, 5, p. 290-301 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Drug Therapy 66%
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors 41%
  • Glatiramer Acetate 41%
  • Chronic Progressive Multiple Sclerosis 39%
  17 Scopus citations

• A retrospective survey of perinatal risk factors of 104 living children with holoprosencephaly

  Stashinko, E. E., Clegg, N. J., Kammann, H. A., Sweet, V. T., Delgado, M. R., Hahn, J. S. & Levey, E. B., Jul 15 2004, In: American Journal of Medical Genetics. 128 A, 2, p. 114-119 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • Holoprosencephaly 100%
  • Child 29%
  • Parturition 17%
  • Basal Forebrain 10%
  • Brain 8%
  53 Scopus citations

• A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis

  Marrie, R. A., Reider, N., Cohen, J., Stuve, O., Sorensen, P. S., Cutter, G., Reingold, S. C. & Trojano, M., Mar 16 2015, In: Multiple Sclerosis Journal. 21, 3, p. 282-293 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Autoimmune Diseases 98%
  • Systematic Reviews 83%
  • Incidence 55%
  • Population 44%
  116 Scopus citations

• A systematic review of the incidence and prevalence of cancer in multiple sclerosis

  Marrie, R. A., Reider, N., Cohen, J., Stuve, O., Trojano, M., Sorensen, P. S., Reingold, S. C. & Cutter, G., Mar 16 2015, In: Multiple Sclerosis Journal. 21, 3, p. 294-304 11 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Multiple Sclerosis 100%
  • Systematic Reviews 83%
  • Incidence 55%
  • Neoplasms 36%
  • Breast Neoplasms 20%
  79 Scopus citations

• A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis

  Marrie, R. A., Reider, N., Cohen, J., Stuve, O., Trojano, M., Cutter, G., Reingold, S. & Sorensen, P. S., Mar 16 2015, In: Multiple Sclerosis Journal. 21, 3, p. 318-331 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Peripheral Vascular Diseases 100%
  • Multiple Sclerosis 74%
  • Systematic Reviews 62%
  • Comorbidity 44%
  • Incidence 41%
  120 Scopus citations

• A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

  Marrie, R. A., Cohen, J., Stuve, O., Trojano, M., Sørensen, P. S., Reingold, S., Cutter, G. & Reider, N., Mar 16 2015, In: Multiple Sclerosis Journal. 21, 3, p. 263-281 19 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Comorbidity 88%
  • Systematic Reviews 83%
  • Incidence 55%
  • Central America 39%
  259 Scopus citations

• A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis

  Marrie, R. A., Reider, N., Cohen, J., Trojano, M., Sorensen, P. S., Cutter, G., Reingold, S. & Stuve, O., Mar 16 2015, In: Multiple Sclerosis Journal. 21, 3, p. 342-349 8 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Sleep Wake Disorders 100%
  • Multiple Sclerosis 80%
  • Epilepsy 76%
  • Systematic Reviews 67%
  • Incidence 44%
  96 Scopus citations

• B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

  Forsthuber, T. G., Cimbora, D. M., Ratchford, J. N., Katz, E. & Stüve, O., Jan 1 2018, In: Therapeutic Advances in Neurological Disorders. 11

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Autoimmunity 100%
  • Cell- and Tissue-Based Therapy 97%
  • B-Lymphocytes 78%
  • Autoimmune Diseases of the Nervous System 62%
  • Transverse Myelitis 29%
  62 Scopus citations

• B cell-directed therapies in multiple sclerosis

  Gasperi, C., Stüve, O. & Hemmer, B., 2016, In: Neurodegenerative disease management. 6, 1, p. 37-47 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Cell- and Tissue-Based Therapy 100%
  • Multiple Sclerosis 93%
  • B-Lymphocytes 81%
  • ocrelizumab 37%
  • ofatumumab 35%
  30 Scopus citations

• B-cell-Targeted therapies in relapsing forms of MS

  Dubey, D., Forsthuber, T., Flanagan, E. P., Pittock, S. J. & Stüve, O., Oct 23 2017, In: Neurology: Neuroimmunology and NeuroInflammation. 4, 6, e405.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Cell- and Tissue-Based Therapy 100%
  • B-Lymphocytes 81%
  • Phase III Clinical Trials 25%
  • Anti-Idiotypic Antibodies 17%
  • Therapeutics 17%
  8 Scopus citations

• B lymphocytes in neuromyelitis optica

  Bennett, J. L., O'Connor, K. C., Bar-Or, A., Zamvil, S. S., Hemmer, B., Tedder, T. F., Von Budingen, H. C., Stuve, O., Yeaman, M. R., Smith, T. J. & Stadelmann, C., Jun 2015, In: Neurology: Neuroimmunology and NeuroInflammation. 2, 3, p. e104

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neuromyelitis Optica 100%
  • B-Lymphocytes 57%
  • Aquaporin 4 50%
  • Autoantibodies 34%
  • Astrocytes 34%
  127 Scopus citations

• Body fluid biomarkers in multiple sclerosis: How far we have come and how they could affect the clinic now and in the future

  Raphael, I., Webb, J., Stuve, O., Haskins, W. & Forsthuber, T., Jan 1 2014, In: Expert review of clinical immunology. 11, 1, p. 69-91 23 p.

  Research output: Contribution to journal › Review article › peer-review

  • Body Fluids 100%
  • Multiple Sclerosis 80%
  • Biomarkers 59%
  • Oligoclonal Bands 26%
  • Cerebrospinal Fluid 15%
  41 Scopus citations

• Botulinum neurotoxin type A.

  Delgado, M. R., Jan 1 2003, In: The Journal of the American Academy of Orthopaedic Surgeons. 11, 5, p. 291-294 4 p.

  Research output: Contribution to journal › Review article › peer-review
  7 Scopus citations

• CD19 as a molecular target in CNS autoimmunity

  Stüve, O., Warnke, C., Deason, K., Stangel, M., Kieseier, B. C., Hartung, H. P., Von Büdingen, H. C., Centonze, D., Forsthuber, T. G. & Knappertz, V., Aug 2014, In: Acta Neuropathologica. 128, 2, p. 177-190 14 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neuromyelitis Optica 100%
  • Autoimmunity 72%
  • Multiple Sclerosis 65%
  • B-Lymphocytes 57%
  • Central Nervous System 54%
  16 Scopus citations

• Central nervous system infections - A potential complication of systemic immunotherapy

  Hemmer, B., Frohman, E., Hartung, H. P. & Stuve, O., Jun 1 2006, In: Current Opinion in Neurology. 19, 3, p. 271-276 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • Central Nervous System Infections 100%
  • Immunotherapy 70%
  • Multiple Sclerosis 56%
  • Central Nervous System 47%
  • Immune System 25%
  27 Scopus citations

• Characterizing the mechanisms of progression in multiple sclerosis: Evidence and new hypotheses for future directions

  Frohman, E., Filippi, M., Stuve, O., Waxman, S. G., Corboy, J., Phillips, J. T., Lucchinetti, C., Wilken, J., Karandikar, N., Hemmer, B., Monson, N. L., De Keyser, J., Hartung, H., Steinman, L., Oksenberg, J. R., Cree, B. A. C., Hauser, S. & Racke, M. K., Sep 2005, In: Archives of neurology. 62, 9, p. 1345-1356 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Direction compound 50%
  • Treatment Effects 13%
  • Illness 6%
  • Therapy 6%
  104 Scopus citations

• Chronic cerebrospinal venous insufficiency and multiple sclerosis

  Bagert, B. A., Marder, E. & Stüve, O., Nov 2011, In: Archives of neurology. 68, 11, p. 1379-1384 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Venous Insufficiency 89%
  • Methodological Problems 27%
  • Scientific Method 24%
  • Critical Analysis 23%
  17 Scopus citations

• Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: Approved therapies and emerging candidates

  Dubey, D., Kieseier, B. C., Hartung, H. P., Hemmer, B., Miller-Little, W. A. & Stuve, O., Jan 1 2014, In: Expert review of clinical immunology. 11, 1, p. 93-108 16 p.

  Research output: Contribution to journal › Review article › peer-review

  • Neuromyelitis Optica 100%
  • Multiple Sclerosis 65%
  • Monoclonal Antibodies 54%
  • Natalizumab 26%
  • Alemtuzumab 25%
  18 Scopus citations

• Combination therapies for multiple sclerosis: Scientific rationale, clinical trials, and clinical practice

  Costello, F., Stuve, O., Weber, M. S., Zamvil, S. S. & Frohman, E., Jun 2007, In: Current opinion in neurology. 20, 3, p. 281-285 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Clinical Trials 73%
  • Therapeutics 18%
  • Autoimmune Experimental Encephalomyelitis 16%
  • Controlled Clinical Trials 15%
  38 Scopus citations

• Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis

  Warnke, C., Stüve, O., Hartung, H. P., Fogdell-Hahn, A. & Kieseier, B. C., Nov 16 2011, In: Neuropsychiatric Disease and Treatment. 7, 1, p. 519-527 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Fingolimod Hydrochloride 100%
  • Multiple Sclerosis 63%
  • Phase III Clinical Trials 21%
  • Safety 20%
  • Marketing 19%
  14 Scopus citations

• Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects

  Weber, M. S., Menge, T., Lehmann-Horn, K., Kronsbein, H. C., Zettl, U., Sellner, J., Hemmer, B. & Stüve, O., Feb 2012, In: Current Pharmaceutical Design. 18, 2, p. 209-219 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Fingolimod 71%
  • Drug 59%
  • Central Nervous System 41%
  • ocrelizumab 33%
  46 Scopus citations

• Defining the clinical course of multiple sclerosis: The 2013 revisions

  Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., & 12 othersLincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E. & Polman, C. H., Jul 15 2014, In: Neurology. 83, 3, p. 278-286 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Phenotype 68%
  • Clinical Trials 29%
  • Advisory Committees 24%
  • Decision Making 18%
  2181 Scopus citations

• Definition and classification of negative motor signs in childhood

  Sanger, T. D., Chen, D., Delgado, M. R., Gaebler-Spira, D., Hallett, M., Mink, J. W., Bastian, A., Ben-Pazi, H., Byl, N., Cermak, S., Chambers, H., Chen, R., Damiano, D., Denckla, M., Deuel, R., DeWald, J. P., Fehlings, D. L., Fowler, E., Garvey, M. A., Gormley, M., & 21 othersHurvitz, E., Jenkins, M., Kluzik, J., Koman, A., Kukke, S., Lebiedowska, M., Levin, M., Matthews, D., Michaels, M. B., Polatajko, H., Rathjen, K., Agramonte, J. R., Rymer, W. Z., Schieber, M., Steinbok, P., Sternad, D., Taub, E., Tilton, A., Van Doornik, J., Ward, S. & Wiznitzer, M., Nov 2006, In: Pediatrics. 118, 5, p. 2159-2167 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Ataxia 100%
  • Apraxias 62%
  • Motor Activity 50%
  • Aptitude 48%
  • Muscles 42%
  199 Scopus citations

• Demographic and clinical features of neuromyelitis optica: A review

  Pandit, L., Asgari, N., Apiwattanakul, M., Palace, J., Paul, F., Leite, M. I., Kleiter, I., Chitnis, T., Iorio, R., Würfel, J., Paul, F., Van Pelt, D., Rogier, H., Tedder, T., Saiz, A., Villoslada, P., Levy, M., Pandit, L., Klawiter, E., Weinshenker, B., & 30 othersWingerchuk, D., Kim, H. J., Tenembaum, S., Palace, J., Leite, M. I., Apiwattanakul, M., Broadley, S., Prayoonwiwat, N., Kleiter, I., Hellwig, K., Han, M., Banwell, B., Van Herle, K., Jacob, A., Hooper, C., Kazutoshi Sato, D., Nakashima, I., Fujihara, K., Bichuetti, D., Aktas, O., De Seze, J., Yeaman, M., Waubant, E., Zamvil, S., Bennett, J., Smith, T., Lana-Peixoto, M., Asgari, N., Greenberg, B. & Stuve, O., Jun 6 2015, In: Multiple Sclerosis Journal. 21, 7, p. 845-853 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Neuromyelitis Optica 100%
  • Demography 47%
  • Aquaporin 4 20%
  • Cuba 19%
  • Peer Review 18%
  249 Scopus citations

• Diagnostic and therapeutic strategies for management of autoimmune encephalopathies

  Dubey, D., Blackburn, K., Greenberg, B., Stuve, O. & Vernino, S., Aug 2 2016, In: Expert review of neurotherapeutics. 16, 8, p. 937-949 13 p.

  Research output: Contribution to journal › Review article › peer-review

  • Brain Diseases 100%
  • Immunomodulation 40%
  • Nervous System Diseases 32%
  • Immunotherapy 30%
  • Early Diagnosis 28%
  25 Scopus citations

• Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety

  Dubey, D., Kieseier, B. C., Hartung, H. P., Hemmer, B., Warnke, C., Menge, T., Miller-Little, W. A. & Stuve, O., Apr 1 2015, In: Expert review of neurotherapeutics. 15, 4, p. 339-346 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Dimethyl Fumarate 100%
  • Relapsing-Remitting Multiple Sclerosis 79%
  • Fumarates 60%
  • Multiple Sclerosis 56%
  • Pharmacokinetics 48%
  63 Scopus citations

• Disease-modifying agents for multiple sclerosis: Recent advances and future prospects

  Menge, T., Weber, M. S., Hemmer, B., Kieseier, B. C., Von Büdingen, H. C., Warnke, C., Zamvil, S. S., Boster, A., Khan, O., Hartung, H. P. & Stüve, O., 2008, In: Drugs. 68, 17, p. 2445-2468 24 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Immunosuppressive Agents 56%
  • B-Lymphocytes 52%
  • TACI receptor-IgG Fc fragment fusion protein 42%
  • laquinimod 41%
  63 Scopus citations

• DNA-based vaccines: The future of multiple sclerosis therapy?

  Stüve, O., Cravens, P. D. & Eagar, T. N., Mar 2008, In: Expert review of neurotherapeutics. 8, 3, p. 351-360 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • DNA Vaccines 100%
  • BHT 3009 93%
  • Multiple Sclerosis 72%
  • T-Lymphocytes 33%
  • Cerebrospinal Fluid 23%
  10 Scopus citations

• Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?

  Cutter, G. R. & Stüve, O., Sep 2014, In: Multiple Sclerosis. 20, 10, p. 1304-1305 2 p.

  Research output: Contribution to journal › Review article › peer-review

  • Natalizumab 100%
  • Progressive Multifocal Leukoencephalopathy 95%
  • Duration of Therapy 26%
  • Polyomavirus 18%
  • Multiple Sclerosis 12%
  42 Scopus citations

• Emerging drugs for primary progressive multiple sclerosis

  Narayan, R. N., Forsthuber, T. & Stüve, O., Apr 3 2018, In: Expert Opinion on Emerging Drugs. 23, 2, p. 97-110 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Chronic Progressive Multiple Sclerosis 100%
  • Pharmaceutical Preparations 30%
  • Multiple Sclerosis 27%
  • ocrelizumab 18%
  • Patient Selection 18%
  11 Scopus citations

• Endocrine disorders associated with holoprosencephaly

  Hahn, J. S., Hahn, S. M., Kammann, H., Barkovich, A. J., Clegg, N. J., Delgado, M. R. & Levey, E., Oct 2005, In: Journal of Pediatric Endocrinology and Metabolism. 18, 10, p. 935-941 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Holoprosencephaly 100%
  • Diabetes Insipidus 50%
  • Hypothyroidism 10%
  • Incidence 9%
  • Growth Hormone 9%
  36 Scopus citations

• Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance1

  Hatanpaa, K. J., Burma, S., Zhao, D. & Habib, A. A., Sep 2010, In: Neoplasia. 12, 9, p. 675-684 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • Neuropathology 100%
  • ErbB Receptors 84%
  • Glioma 82%
  • Signal Transduction 69%
  • epidermal growth factor receptor VIII 33%
  366 Scopus citations

• Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: Opportunities and obstacles

  Neuhaus, O., Stüve, O., Zamvil, S. S. & Hartung, H. P., 2005, In: CNS Drugs. 19, 10, p. 833-841 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors 100%
  • Multiple Sclerosis 90%
  • Placebos 15%
  • Phase II Clinical Trials 13%
  • Atorvastatin 13%
  15 Scopus citations

• Holoprosencephaly: A review

  Clegg, N. J., Gerace, K. L., Sparagana, S. P., Hahn, J. S. & Delgado, M. R., 2002, In: Neurodiagnostic Journal. 42, 2, p. 59-72 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Holoprosencephaly 100%
  • Electroencephalography 58%
  • Child 29%
  • Epilepsy 29%
  • Sleep 26%
  9 Scopus citations

• Identification of targets and new developments in the treatment of multiple sclerosis-focus on cladribine

  Warnke, C., Wiendl, H., Hartung, H. P., Stüve, O. & Kieseier, B. C., Dec 1 2010, In: Drug Design, Development and Therapy. 4, p. 117-126 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • Cladribine 100%
  • Multiple Sclerosis 48%
  • Fingolimod 34%
  • Drug 28%
  • Fingolimod Hydrochloride 25%
  15 Scopus citations

• Immune-mediated CNS diseases: A review on nosological classification and clinical features

  Zettl, U. K., Stüve, O. & Patejdl, R., Jan 2012, In: Autoimmunity Reviews. 11, 3, p. 167-173 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Central Nervous System Diseases 100%
  • Immune System Diseases 64%
  • Marburg Virus Disease 54%
  • Multiple Sclerosis 53%
  • Diffuse Cerebral Sclerosis of Schilder 50%
  82 Scopus citations

• Immune response to immunotherapy: The role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

  Hemmer, B., Stüve, O., Kieseier, B., Schellekens, H. & Hartung, H. P., Jul 2005, In: Lancet Neurology. 4, 7, p. 403-412 10 p.

  Research output: Contribution to journal › Review article › peer-review

  • Interferon-beta 100%
  • Neutralizing Antibodies 86%
  • Multiple Sclerosis 76%
  • Immunotherapy 76%
  • Relapsing-Remitting Multiple Sclerosis 17%
  73 Scopus citations

• Immune surveillance of the central nervous system in multiple sclerosis - Relevance for therapy and experimental models

  Hussain, R. Z., Hayardeny, L., Cravens, P. C., Yarovinsky, F., Eagar, T. N., Arellano, B., Deason, K., Castro-Rojas, C. & Stüve, O., Nov 15 2014, In: Journal of Neuroimmunology. 276, 1-2, p. 9-17 9 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Theoretical Models 92%
  • Central Nervous System 83%
  • Central Nervous System Diseases 82%
  • Autoimmune Diseases of the Nervous System 57%
  25 Scopus citations

• Immunologic Mechanisms of Multiple Sclerosis

  Frohman, E., Eagar, T., Monson, N. L., Stuve, O. & Karandikar, N., Nov 2008, In: Neuroimaging Clinics of North America. 18, 4, p. 577-588 12 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Nervous System 92%
  • Young Adult 45%
  • Central Nervous System 41%
  • Inflammation 33%
  23 Scopus citations

• Immunomodulation in multiple sclerosis

  Leussink, V. I., Stüve, O., Hö;rste, G. M. Z. & Kieseier, B. C., 2010, In: Hot Topics in Neurology and Psychiatry. 9, p. 17-21 5 p.

  Research output: Contribution to journal › Review article › peer-review

  • Immunomodulation 100%
  • Multiple Sclerosis 76%
  • Autoimmune Diseases of the Nervous System 44%
  • Glatiramer Acetate 42%
  • Interferon-beta 33%

• Immunomodulatory treatment strategies in multiple sclerosis

  Kieseier, B. C., Wiendl, H., Leussink, V. I. & Stüve, O., Dec 1 2008, In: Journal of Neurology. 255, SUPPL. 6, p. 15-21 7 p.

  Research output: Contribution to journal › Review article › peer-review

  • Multiple Sclerosis 100%
  • Autoimmune Diseases of the Nervous System 57%
  • Glatiramer Acetate 54%
  • Interferon-beta 43%
  • Immunomodulation 43%
  26 Scopus citations

• Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: In search of biomarkers

  Alvermann, S., Hennig, C., Stüve, O., Wiendl, H. & Stangel, M., Jul 2014, In: JAMA neurology. 71, 7, p. 905-912 8 p.

  Research output: Contribution to journal › Review article › peer-review

  • Immunophenotyping 100%
  • Multiple Sclerosis 69%
  • Cerebrospinal Fluid 68%
  • Biomarkers 51%
  • Leukocytes 25%
  52 Scopus citations

• Immunosuppression in clinical practice: AAApproaches to individualized therapy

  Chan, A., Stüve, O. & Von Ahsen, N., Dec 2008, In: Journal of neurology. 255, SUPPL. 6, p. 22-27 6 p.

  Research output: Contribution to journal › Review article › peer-review

  • Immunosuppression 100%
  • Immunosuppressive Agents 91%
  • Therapeutic Index 45%
  • Pharmacogenetics 41%
  • Metabolic Networks and Pathways 37%
  4 Scopus citations

• Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

  Boster, A., Edan, G., Frohman, E., Javed, A., Stuve, O., Tselis, A., Weiner, H., Weinstock-Guttman, B. & Khan, O., Feb 2008, In: The Lancet Neurology. 7, 2, p. 173-183 11 p.

  Research output: Contribution to journal › Review article › peer-review

  • Immunosuppression 100%
  • Multiple Sclerosis 97%
  • Guidelines 70%
  • Natalizumab 45%
  • Immunosuppressive Agents 26%
  68 Scopus citations